Cite
Zhang Q, Shi C, Han L, et al. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in . Oncotarget. 2018;9(8):8027-8041doi: 10.18632/oncotarget.24261.
Zhang, Q., Shi, C., Han, L., Jain, N., Roberts, K. G., Ma, H., Cai, T., Cavazos, A., Tabe, Y., Jacamo, R. O., Mu, H., Zhao, Y., Wang, J., Wu, S. C., Cao, F., Zeng, Z., Zhou, J., Mi, Y., Jabbour, E. J., Levine, R., Tasian, S. K., Mullighan, C. G., Weinstock, D. M., Fruman, D. A., & Konopleva, M. (2018). Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in . Oncotarget, 9(8), 8027-8041. https://doi.org/10.18632/oncotarget.24261
Zhang, Qi, et al. "Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in ." Oncotarget vol. 9,8 (2018): 8027-8041. doi: https://doi.org/10.18632/oncotarget.24261
Zhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Cai T, Cavazos A, Tabe Y, Jacamo RO, Mu H, Zhao Y, Wang J, Wu SC, Cao F, Zeng Z, Zhou J, Mi Y, Jabbour EJ, Levine R, Tasian SK, Mullighan CG, Weinstock DM, Fruman DA, Konopleva M. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in . Oncotarget. 2018 Jan 17;9(8):8027-8041. doi: 10.18632/oncotarget.24261. eCollection 2018 Jan 30. PMID: 29487712; PMCID: PMC5814279.
Copy
Download .nbib